Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics Inc. (ZVRA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,048,653 | $28,097,652 | +253% | 0.23% |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,924,021 | $20,292,705 | +21% | 1.02% |
| 3. | Altium Capital Jacob Gottlieb | 1,700,000 | $11,798,000 | +47% | 3.47% |
| 4. | 683 Capital Partners Ari Zweiman | 1,225,000 | $8,501,500 | +54% | 0.64% |
| 5. | Stonepine Capital Timothy P. Lynch | 700,000 | $4,858,000 | 3.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.92 | 500 | Director | 1,500 | 2024-10-11 | Filing | |
| $6.77 | 2,000 | Officer | 18,469 | 2024-07-17 | Filing | |
| $6.81 | 10,000 | Director | 20,000 | 2024-07-16 | Filing | |
| $5.87 | 10,000 | Director | 30,000 | 2024-07-12 | Filing | |
| $5.13 | 500 | Officer | 3,500 | 2023-09-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,410,289 | $15,787,393 | 0% | |
| 2. | 1,645,140 | $10,775,667 | 0% | |
| 3. | 729,179 | $4,776,597 | 0% | |
| 4. | 636,060 | $4,166,193 | 0% | |
| 5. | 387,427 | $2,537,647 | 1.14% |
News See All
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics' First Quarter 2024 Corporate Update and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics Third Quarter 2023 Corporate Updates and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call.